Market Cap 585.95M
Revenue (ttm) 23.61M
Net Income (ttm) -105.51M
EPS (ttm) N/A
PE Ratio 9.69
Forward PE 22.30
Profit Margin -446.89%
Debt to Equity Ratio 0.46
Volume 1,320,100
Avg Vol 1,163,026
Day's Range N/A - N/A
Shares Out 58.71M
Stochastic %K 49%
Beta 0.91
Analysts Strong Sell
Price Target $23.00

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology
Sector: Healthcare
Phone: 321 939 3416
Website: zevra.com
Address:
1180 Celebration Boulevard, Suite 103, Celebration, United States
ZVRA100
ZVRA100 Mar. 18 at 12:19 AM
$ZVRA just waiting for Q1 2026 call in May now… expecting ~$37M revenue, ~$14M earning and ~$0.20 EPS. 170-175 US miplyffa patients.
1 · Reply
poctordoker
poctordoker Mar. 17 at 7:52 PM
0 · Reply
KemPharm_rocks
KemPharm_rocks Mar. 17 at 6:00 PM
$ZVRA The new Zevra isn’t the old Zevra folks... let it go! Moving forward it’s win/win... stay the course and makes 100s of millions in rare disease, or we get bought out at $30-$36 and just count our profits... and finally close this f’ing board. There, I’ve fixed Mando’s price typo 🤣
1 · Reply
PencilNeckGeek
PencilNeckGeek Mar. 17 at 5:53 PM
$ZVRA lol at this absolute turd of a stock not being able to hold 10 bucks with seemingly good earnings. It earnings can't move it, nothing will
0 · Reply
ProphetofProfits20
ProphetofProfits20 Mar. 17 at 3:56 PM
$ZVRA Geez, not good at some of these computer things. I think Travis being hired by them would be the funniest thing I've seen in a while, lol.
0 · Reply
MandoTrades
MandoTrades Mar. 17 at 3:55 PM
$ZVRA The new Zevra isn't the old Zevra folks... let it go! Moving forward it's win/win... stay the course and makes 100s of millions in rare disease, or we get bought out at $20-25 and just count our profits... and finally close this f'ing board.
3 · Reply
ProphetofProfits20
ProphetofProfits20 Mar. 17 at 3:54 PM
0 · Reply
ProphetofProfits20
ProphetofProfits20 Mar. 17 at 3:53 PM
0 · Reply
DevAd
DevAd Mar. 17 at 3:43 PM
$ZVRA Conspiracy time: What if Commave goes back to Travis Mickle and asks to restart the SDX program?
3 · Reply
intowits
intowits Mar. 17 at 3:28 PM
$ZVRA "Zevra Therapeutics' involvement in South America includes commercial rights for a drug used to treat Niemann-Pick disease type C (NPC) and exclusive rights to clinical data for the drug candidate CELIPROLO." "Zevra obtained the exclusive right from Aventis to use celiprolol data in North and South America." "We have obtained the exclusive right in North and South America from Aventis to reference the celiprolol data included in the marketing authorization application dossier filed with and approved by the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”)." "In addition, our wholly-owned subsidiary, Acer Therapeutics, Inc. (“Acer”) has licensed exclusive worldwide rights to the data from the Phase 3 clinical trial known as the BBEST trial which was sponsored by L’Assistance Publique Hôpitaux de Paris (“AP-HP”)."
0 · Reply
Latest News on ZVRA
Zevra Therapeutics, Inc. Announces CFO Transition

Nov 20, 2025, 4:05 PM EST - 4 months ago

Zevra Therapeutics, Inc. Announces CFO Transition


Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 8:43 PM EDT - 7 months ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript


Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:45 PM EDT - 10 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript


Zevra Therapeutics Files Preliminary Proxy

Mar 31, 2025, 4:12 PM EDT - 1 year ago

Zevra Therapeutics Files Preliminary Proxy


Zevra to Participate at Upcoming Investor Conferences

Feb 24, 2025, 4:02 PM EST - 1 year ago

Zevra to Participate at Upcoming Investor Conferences


Zevra Therapeutics Announces Organizational Changes

Dec 6, 2024, 5:00 PM EST - 1 year ago

Zevra Therapeutics Announces Organizational Changes


ZVRA100
ZVRA100 Mar. 18 at 12:19 AM
$ZVRA just waiting for Q1 2026 call in May now… expecting ~$37M revenue, ~$14M earning and ~$0.20 EPS. 170-175 US miplyffa patients.
1 · Reply
poctordoker
poctordoker Mar. 17 at 7:52 PM
0 · Reply
KemPharm_rocks
KemPharm_rocks Mar. 17 at 6:00 PM
$ZVRA The new Zevra isn’t the old Zevra folks... let it go! Moving forward it’s win/win... stay the course and makes 100s of millions in rare disease, or we get bought out at $30-$36 and just count our profits... and finally close this f’ing board. There, I’ve fixed Mando’s price typo 🤣
1 · Reply
PencilNeckGeek
PencilNeckGeek Mar. 17 at 5:53 PM
$ZVRA lol at this absolute turd of a stock not being able to hold 10 bucks with seemingly good earnings. It earnings can't move it, nothing will
0 · Reply
ProphetofProfits20
ProphetofProfits20 Mar. 17 at 3:56 PM
$ZVRA Geez, not good at some of these computer things. I think Travis being hired by them would be the funniest thing I've seen in a while, lol.
0 · Reply
MandoTrades
MandoTrades Mar. 17 at 3:55 PM
$ZVRA The new Zevra isn't the old Zevra folks... let it go! Moving forward it's win/win... stay the course and makes 100s of millions in rare disease, or we get bought out at $20-25 and just count our profits... and finally close this f'ing board.
3 · Reply
ProphetofProfits20
ProphetofProfits20 Mar. 17 at 3:54 PM
0 · Reply
ProphetofProfits20
ProphetofProfits20 Mar. 17 at 3:53 PM
0 · Reply
DevAd
DevAd Mar. 17 at 3:43 PM
$ZVRA Conspiracy time: What if Commave goes back to Travis Mickle and asks to restart the SDX program?
3 · Reply
intowits
intowits Mar. 17 at 3:28 PM
$ZVRA "Zevra Therapeutics' involvement in South America includes commercial rights for a drug used to treat Niemann-Pick disease type C (NPC) and exclusive rights to clinical data for the drug candidate CELIPROLO." "Zevra obtained the exclusive right from Aventis to use celiprolol data in North and South America." "We have obtained the exclusive right in North and South America from Aventis to reference the celiprolol data included in the marketing authorization application dossier filed with and approved by the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”)." "In addition, our wholly-owned subsidiary, Acer Therapeutics, Inc. (“Acer”) has licensed exclusive worldwide rights to the data from the Phase 3 clinical trial known as the BBEST trial which was sponsored by L’Assistance Publique Hôpitaux de Paris (“AP-HP”)."
0 · Reply
intowits
intowits Mar. 17 at 3:25 PM
$ZVRA Per Neil @ JPM: (Celiprolol) "as of the end of Q3, we've enrolled 44 of the 150 patients. As I mentioned before, it is an event-driven trial. And the interim analysis is that 28 events, of which if we hit the positive marker there, we will then move towards a -- sorry, then WE DON'T HAVE TO MOVE TOWARDS THE FINAL EVENT RATES, WHICH IS 46 EVENTS."
0 · Reply
bizness1957
bizness1957 Mar. 17 at 3:02 PM
$ZVRA 5 million shares short
1 · Reply
intowits
intowits Mar. 17 at 2:43 PM
$ZVRA Miplyffa patent term extension: "Following the 9/25 notice, a 180-day period ending 3/30/26 is allowed for any person to file a "due diligence petition" challenging the FDA's determination of the review period." "If no challenges are filed, the USPTO generally issues the formal Notice of Final Determination shortly (1 month - May?) after this 180-day window expires." "Once a determination is made pursuant to 37 CFR 1.750 that a patent is eligible for extension of its term, a certificate of extension, under seal, will be issued to the patent owner. Following the one-month period provided in the Notice of Final Determination, the certificate of extension is prepared and signed by the Director. Upon issuance of the certificate of extension, the file wrapper available in the USPTO patent electronic filing system will include an image of the certificate of extension. A courtesy copy of the certificate is sent to the regulatory agency." (FDA)
2 · Reply
DaveESIX
DaveESIX Mar. 17 at 2:19 PM
$ZVRA in the situation we were in i like the sale... Neil put us in that situation. I don't like Neil. Neither does the street... clearly. Time for BOD to act
0 · Reply
111ggg
111ggg Mar. 17 at 2:18 PM
$ZVRA cannot remember. Did I say 10 was fair value?
1 · Reply
bizness1957
bizness1957 Mar. 17 at 2:07 PM
$ZVRA forward PE 12 and growing at 100%
0 · Reply
Pentium
Pentium Mar. 17 at 2:00 PM
$ZVRA Snatched 5.8k @ 9.79-9.85 more orders in waiting for any more foolishness.
0 · Reply
Notsinginganymore
Notsinginganymore Mar. 17 at 1:24 PM
$ZVRA Interesting that ChatGPT says Clifton is still at Zevra. Only when I challenged it did it say "Erm, yeah, he's not there anymore (was he ever really there?)."
1 · Reply
Trend123
Trend123 Mar. 17 at 1:13 PM
$ZVRA $COLL bought jornay ( a sub Azstarys without the the SDX possibilities ) for 500M$ when Neil was working there .
1 · Reply
Torn891
Torn891 Mar. 17 at 12:53 PM
$ZVRA Clearly the market has absolutely no faith in Neil going forward. To one of the comments below. This sale IS good news but it was also a mop up of Neils own fuck up. The fact that this sold off on a profitable earnings and a perfectly clean balance sheet with 4 bucks in MC in cash means this is either a BO candidate for current investors or is just going to keep the same tutes in and stagnate even if Neil grows Myplyffa. My opinion only
1 · Reply
KemPharm_rocks
KemPharm_rocks Mar. 17 at 12:37 PM
$ZVRA Let’s see if the market sees what we are seeing
0 · Reply
DaveESIX
DaveESIX Mar. 17 at 12:02 PM
$ZVRA market cap of $585M. How much cash do we have on hand now and how much are we generating per quarter with Mylyppa? (Sorry i could look but you guys know everything and it's a good point to keep reiterating to the board). We have a lot of green and cash flow... not common for small cap bio
1 · Reply